Newsletter · 2026-07-20 · Ashutosh Agarwal

Lilly Goes on a Buying Spree as Cheap GLP-1 Copies Land Abroad - The GLP-1 Complex - Week of July 20, 2026

GLP-1 podcast intelligence for the week of July 14 to 20, 2026. Cheap semaglutide generics drove volumes sixfold in India, Eli Lilly extended its buying spree with a $3.8 billion psychedelics deal, Medicare began covering the drugs for seniors, and a compounding bill in Congress could squeeze the gray-market supply as the fight shifts from shots to pills.

The GLP-1 Complex

Week of July 14–20, 2026: Lilly Goes on a Buying Spree as Cheap GLP-1 Copies Land Abroad

The story this week wasn't a new blockbuster trial. It was the plumbing of the whole business: the first cheap copies of these drugs are landing overseas, the US government just started paying for them for seniors, and Eli Lilly is spending like a company that already sees the far side of its own gold rush. Underneath the noise, the podcasts kept circling one idea, the race has quietly shifted from "who loses the most weight" to "who can make a pill, keep patients on it, and actually supply the world."

TL;DR

• Generics are here, abroad, and they're expanding the market, not shrinking it. In India, cheap copycat semaglutide sent volumes up sixfold in two months. That's the template global investors are watching for the US and Europe.

• Lilly is on a buying spree. A $3.8 billion deal for a psychedelics company, on top of a run of others, a very deliberate hedge against the day its obesity franchise stops growing.

• Washington is now a two-front war for these drugs. Medicare started covering them for seniors on July 1, while a bill working through Congress could choke off the pharmacies that made cheap knock-offs during the shortage.

What's new

Cheap semaglutide is already reshaping demand, just not here yet. On Morgan Stanley's Thoughts on the Market, pharma analysts Terence Flynn and Thibault Boutherin walked through the first three markets where semaglutide (the drug behind Ozempic and Wegovy) has lost patent protection: India, Canada, and Brazil. India is the eye-opener. The patent expired there in March 2026, thirteen companies rushed in with 26 different generic versions, and by April the copies had grabbed 80% of semaglutide volume, while total volume ran six times higher than it had been in February. Their team now expects India's GLP-1 market to grow from $125 million in 2025 to more than $1 billion by 2030, because prices fell, not despite it. The catch for anyone extrapolating to the US: the American patent doesn't expire until 2032 (Europe in 2031), so the branded giants have years of runway left at home.

Lilly keeps buying, this time, psychedelics. On Biotech Hangout, the panel (led by a biotech executive named John, with fellow investors Sam and Matt) unpacked Lilly's $3.8 billion acquisition of Atai Life Sciences, $2.8 billion upfront plus $1 billion tied to a future milestone, for a nasal treatment for hard-to-treat depression. Sam called the strategy the "Amazonification of pharma": Lilly is now planting flags in seemingly every corner of medicine. The logic is explicitly defensive. As Sam put it, the buying spree "speaks volumes to how they're thinking about the future, which will inevitably include some kind of plateau or pressure on their obesity franchise." John added that Lilly, now the industry's first trillion-dollar company, is pivoting toward preventing disease rather than treating it, and using LillyDirect, its own telehealth-and-delivery channel, to sell straight to patients and route around the pharmacy middlemen (the PBMs). This matters for numbers because it tells you how Lilly plans to defend its margins and its growth when the obesity tailwind eventually fades.

The real fight is now over pills, not shots. The On The Pen GLP-1 News host framed the week's pipeline news bluntly: "The next major battle isn't over who has the best weekly injection. It's over who builds likely the best oral therapy that patients actually want to stay on long term." The fresh data point was from China: Chylero Therapeutics and its partner Hengrui Medicine reported positive late-stage results for an oral pill, roughly 10-11% weight loss over about ten months, enough to make it a contender against Lilly's own pill, orforglipron. The asterisk: analysts zeroed in on the stomach side effects, which one described as "alarming." The host also flagged Novo Nordisk's oral version launching in Europe and Pfizer buying its way in through its acquisition of Metsera. Translation for the market: efficacy alone no longer wins; a pill has to be tolerable, easy to stay on, and cheap to manufacture at massive scale.

Medicare opened the door for seniors, a potential watershed. The Plus SideZ bonus episode featured Dr. Michael Albert, chief medical officer at Vineyard Telehealth, on the new Medicare "Bridge" program that started July 1. His framing is the one investors should sit with: this is "the first time since Part D was passed in 2003 that the government has committed to covering obesity medications for the specific intent of helping people manage their weight." Seniors who qualify pay a flat $50 a month, and, a nice detail, that copay is carved out so it doesn't count against their deductible. The program is a pilot running only through the end of 2027, aimed at people with a body mass index of 27-plus with a related condition, or 35-plus on its own. Why it moves numbers: if the pilot works, Dr. Albert notes, commercial insurers and employer health plans "typically follow suit." Morgan Stanley's analysts sized the near-term prize at roughly 18 million additional people over 65.

A bill in Congress could kill the cheap gray-market supply. On the Pharmacy Podcast Network, compounding-policy experts David Glazer and Amy Kamarainen dissected the proposed "SAFE Drugs Act." During the long GLP-1 shortage, small neighborhood compounding pharmacies (known as 503As) were legally allowed to mix their own versions and became a huge, cheap source of supply. The bill would sharply restrict that during future shortages. The pointed detail: both original House sponsors come from Indiana, home to one of the largest GLP-1 makers. Their read is that the bill "doesn't have a lot to do with improving patient safety. It has to do with protecting the market share of the pharmaceutical companies that make the drugs that are going into shortage." For the branded players, that's a quiet tailwind; for the compounding and telehealth ecosystem, it's a real threat.

The debate

The bull case (well voiced this week): Lower prices grow the pie rather than shrinking it, India is the live proof. The market keeps segmenting: Morgan Stanley's Flynn pointed out that tirzepatide (the drug in Mounjaro and Zepbound, which hits two hormone targets instead of one) already holds about 60% US share and delivers "not only better efficacy, but also improved tolerability," so premium branded drugs can keep growing even as cheap generics flood the low end. And the clinical story keeps widening: on Consumerpedia, University of Washington endocrinologist Dr. David Cummings laid out that tirzepatide produces about 22% weight loss at a year (versus roughly 15% for semaglutide) and, in rigorous trials, cuts heart attacks and strokes, heart failure, serious kidney and liver events, arthritis, and sleep apnea. New pills and new pathways (amylin, glucagon) are coming, with "several introduced into the market each year for the next five at least." A bigger, stickier, more medically essential category is the bull thesis in one breath.

The bear case (also voiced, and worth taking seriously): These drugs don't work for everyone, and people quit. On The Immunology Podcast, Maynooth University professor Dr. Andrew Hogan noted GLP-1s are "not effective for maybe 30% of the population," that patients essentially need them for life, and that if you stop, "you regain the vast majority of weight within 12 months." That points to a real ceiling on the persistence, how long people stay on the drug, that underpins the most aggressive revenue forecasts. Add generic erosion at the low end, a China pill with "alarming" side effects but real efficacy, and messy government cross-currents (Medicare giveth, the SAFE Act debate taketh away), and you have plenty for the skeptics. The one gap: no one this week made the case that a specific incumbent is about to lose, the bear argument was about the category's limits, not a single stock's downfall.

Read-throughs

Medtech is getting caught in the crossfire, and the AI trade. On Stock Club, hosts Mike and his co-host ran through a beaten-up medical-device group, tying the damage partly to money fleeing "quality names to go chase the AI bubble" and partly to GLP-1s. They singled out Dexcom (DXCM, glucose monitors) and ResMed (RMD, sleep-apnea machines) as being "at the wrong end of the GLP1 trend", the fear being that if a weekly shot fixes diabetes and sleep apnea, you need fewer monitors and machines. Their stated scorecard for the year: ResMed down about 19%, Dexcom up 15% but still more than 50% below its 2021 peak, Intuitive Surgical (robotic surgery) down 27%, and Boston Scientific down 54%. Worth noting the counter-evidence from Dr. Cummings on Consumerpedia, these drugs reduce sleep apnea in trials, which is exactly ResMed's worry made clinical.

Restaurants and packaged food have a real, measurable problem. On We Fixed It, You're Welcome, consumer researcher Lisa shared proprietary numbers that should make food investors sit up: across the 60 restaurant brands she tracks, the share of current customers already on a GLP-1 ranges from 12% to 43%. As she put it, 12% is "a niche within your current user base," but 43% is "recalibration... we stopped the press." She also flagged a surge of men starting the drugs in the last six months, a demographic the marketing has largely ignored, and noted Medicare's new $50 copay just handed the category a fresh wave of older, higher-spending customers. One throwaway that captures the belt-tightening: McDonald's is reportedly ending free refills.

On the ground, the drugs are doing what the bulls say. For color on why demand is so sticky, author Charles Duhigg described on The James Altucher Show losing 45 pounds on Zepbound over about two years, with the drug quieting the "food noise" in his head long enough to build new habits, a neat, human version of the persistence question that decides these companies' revenue.